Point72 Asset Management
LCTX icon

Point72 Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Point72 Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$481K Buy
304,363
+144,955
+91% +$244K ﹤0.01% 3133
2025
Q4 		$266K Buy
+159,408
New +$276K ﹤0.01% 3523
2023
Q2 		– Sell
-13,786
Closed -$20.7K – 2493
2023
Q1 		$20.7K Buy
+13,786
New +$19.2K ﹤0.01% 1966

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's LCTX Position: Q1 2026 in Review

Point72 Asset Management increased its Lineage Cell Therapeutics (LCTX) stake by 91% in Q1 2026, buying an estimated $244K and bringing the position to 304,363 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #3133.

Point72 Asset Management first reported a position in LCTX in Q1 2023 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Point72 Asset Management held 304,363 shares of Lineage Cell Therapeutics worth $481K as of Q1 2026.
  • Point72 Asset Management bought 144,955 Lineage Cell Therapeutics shares in Q1 2026, an estimated $244K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3133 holding.
  • Point72 Asset Management first reported a position in Lineage Cell Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.